RootLock, Artificial Knee Joint 'CentLock' Enters US Market

Spinal implant company L&K Biomed announced on the 2nd that its affiliate Rootloc will export its artificial knee joint product 'CentLoc,' produced at its own factory, to the United States. This is the first case of a domestic venture company exporting artificial knee joints to the U.S.

To enter the U.S. market, Rootloc signed a sales partnership agreement to utilize the hospital network of L&K Biomed's U.S. local sales corporation, Aegis Spine.

Jongjin Park, CEO of Rootloc, stated, "Hospitals in the U.S. using Aegis Spine's spinal implant products have strong demand for artificial knee joint products manufactured in Korea." He added, "We expect this to significantly contribute to the company's growth as sales increase in the U.S. market."

The U.S. market is the largest, accounting for over 50% of the global artificial joint market, and the hospital fees for artificial joints in the U.S. are higher than those covered by domestic health insurance.

Rootloc began developing and selling its own artificial joint product, CentLoc, designed to fit the body type of Koreans. It succeeded in domesticating artificial joints in Korea, which had previously relied on foreign products. It is the only domestic venture company to develop artificial knee joints and receive FDA approval in the U.S.

Rootloc has its own production plant in Cheonan, Chungnam Province, and obtained manufacturing approval from the Ministry of Food and Drug Safety. Established in 2014, Rootloc was listed on the KONEX market in December 2020.